健友股(gu)份(603707)7月31日晚(wan)間公(gong)(gong)(gong)告，公(gong)(gong)(gong)司近日收(shou)到(dao)加拿(na)(na)大(da)(da)衛生部簽發的依諾肝素(su)鈉注射液批(pi)準通(tong)知，標(biao)志著公(gong)(gong)(gong)司已具備在加拿(na)(na)大(da)(da)市(shi)(shi)場銷售該藥(yao)(yao)品的資(zi)格(ge)。該藥(yao)(yao)品適應癥為預防靜脈血(xue)栓(shuan)栓(shuan)塞性疾(ji)病（預防靜脈內血(xue)栓(shuan)形成(cheng)），特別(bie)是與(yu)骨科或普外手(shou)術有關(guan)的血(xue)栓(shuan)形成(cheng)等。截至目前(qian)，公(gong)(gong)(gong)司依諾肝素(su)鈉已獲得美國(guo)、歐(ou)洲、巴西(xi)、厄(e)瓜多爾、加拿(na)(na)大(da)(da)等多個國(guo)家(jia)的上市(shi)(shi)批(pi)準。